The Active Pharmaceutical Ingredient Innovation Center (APIIC), a consortium of biotechnology industry, policy and academic leaders, said in a whitepaper released to the media on Jan. 24, that reshoring the manufacture of essential, life-saving pharmaceuticals was urgently needed.
A recent study suggests that Americans prefer locally produced medications if they are unclear where the product was made or if the lab has received bad reviews from an FDA inspection.
In the wake of the COVID pandemic, consumers have become painfully aware of America’s heavy dependence on imports. The recent Amoxicillin shortage in hospitals has
Trump’s call to reshore pharmaceutical production, especially critical medicine in short supply, will set the table for other presidential candidates. Reshoring America’s medicine supply chain is increasingly mainstream, and an easy sell to voters.
The U.S. is increasingly dependent on imports for drugs. One reason: a tax avoidance scheme that pits U.S. manufacturing up against Europe. What can be done about this problem?